You are here: Home: PCU Think Tank 1 | 2006: Audio Program Guide: PCU Think Tank 1 | 2006 Audio
 
  Go to Section 1
Go to Section 2
Go to Section 3
Go to Section 4
Go to Section 5
Go to Section 6
Go to Section 7
Go to Section 8
Go to Section 9
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Section 1: Salvage Cryotherapy
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Cryotherapy for the treatment of local recurrence following radiation therapy
Track 3 Advances in cryotherapy techniques
Track 4 Lack of standardization of cryotherapy techniques
Track 5 Randomized trial comparing cryotherapy to radiation therapy for locally advanced disease
Track 6 Strategies for accruing patients to clinical trials in Canada

Track 7 Obstacles to physician support of clinical trials
Track 8 Impact of physician education on participation in clinical trials
     
Section 2: PSA as a Prognostic Indicator
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Natural history of prostate cancer
Track 3 Risk factors for prostate cancer mortality
Track 4 Predictive value of PSA doubling time versus other variables
Track 5 Changes in PSA doubling time as the disease progresses
Track 6 Determination of PSA doubling time

Track 7 Definition of PSA recurrence
     
Section 3: Treatment for Patients with PSA-Only Relapse
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Selection of patients to treat for PSA-only relapse
Track 3 Treatment alternatives for patients with PSA-only relapse
Track 4 Determination of appropriate endpoints for clinical trials for PSA-only recurrence
Track 5 Proposed clinical trial of androgen deprivation therapy with or without docetaxel for PSA-only recurrence
Track 6 Chemotherapy for the treatment of PSA-only disease in clinical practice

Track 7 Relationship between PSA doubling time and clinical disease progression
Track 8 Calculation of PSA doubling time
     
Section 4: Combined Androgen Blockade
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Evolution of maximum androgen blockade (MAB) therapy
Track 3 Ketoconazole as second-line hormonal therapy for prostate cancer
Track 4 Use of MAB in clinical practice
Track 5 Benefit of MAB in the treatment of metastatic disease
Track 6 Clinical trials evaluating MAB

     
Section 5: Intermittent Androgen Deprivation
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Evolution of clinical research on intermittent androgen therapy
Track 3 Intermittent versus continuous androgen therapy
Track 4 Potential role of 5-alpha-reductase inhibitors in managing prostate cancer
Track 5 Mechanism of action of 5-alpha-reductase inhibitors
Track 6 Selection of patients for intermittent androgen therapy

Track 7 Survival rates with combined versus continuous and early versus delayed therapy

     
Section 6: Adjuvant and Neoadjuvant Systemic Therapies
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Combining hormonal therapy with high-dose radiation therapy
Track 3 Clinical trial of neoadjuvant docetaxel
Track 4 Radiation therapy with hormonal therapy for the treatment of locally advanced or high-risk disease
Track 5 Adjuvant therapy for patients with high-risk disease after radical prostatectomy
Track 6 Role of hormonal therapy: Cure or palliation

Track 7 Cardiovascular morbidity in patients receiving androgen deprivation therapy

     
Section 7: Radiation Therapy for High-Risk Disease
  Click here to download the entire segment  
Track 1 Introduction
Track 2 SWOG-S8794: Phase III trial comparing adjuvant radiation therapy to no adjuvant therapy following radical prostatectomy
Track 3 Selection of patients for postprostatectomy radiation therapy based on risk
Track 4 Efficacy of adjuvant versus salvage radiation therapy
     
Section 8: Clinical Trials of Adjuvant Chemotherapy for High-Risk Disease
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Clinical trials evaluating adjuvant chemotherapy for patients at high risk
Track 3 Importance of completing clinical trials of adjuvant chemotherapy in prostate cancer
Track 4 Redefining high-risk versus intermediate-risk cases
Track 5 TAX-3501: Immediate adjuvant leuprolide with or without docetaxel versus deferred therapy followed by the same therapeutic options in patients at high risk of relapse postprostatectomy
     
Section 9: Treatment of Patients with Metastatic Disease
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Efficacy and tolerability of docetaxel-based chemotherapy in metastatic disease
Track 3 Ongoing trials evaluating docetaxel in combination with novel agents for hormone-refractory prostate cancer
Track 4 Improved quality of life with docetaxel-based chemotherapy in the treatment of metastatic disease
Track 5 Effects of long-term androgen deprivation on bone density
Track 6 Benefit of vitamin D and calcium for patients receiving androgen deprivation therapy

Track 7 Monitoring bone mineral density in patients receiving androgen deprivation therapy